Rafa Laboratories Overview
Rafa Laboratories is a pharmaceutical company that markets, manufactures, and distributes consumer health products and prescription and over-the-counter medicines, mainly proprietary formulations as well as generic formulations. The company manufactures a wide variety of medications based on in-house development and through external agreements. Rafa Laboratories is also involved in marketing drugs produced by international corporations such as Dr. Falk Pharma, Helsinn Healthcare, Boehringer Ingelheim, Purdue Pharma, 3M Healthcare, United Therapeutics, and Mundipharma. Rafa Laboratories received FDA approval for their 10 mg midazolam autoinjector, which can treat seizures caused by nerve agent exposure.
Latest News
growth-positive
שווי של 1.2 מיליארד שקל: פימי במגעים למכירת 10%–15% מרפא
Almost four years after acquiring a controlling stake (88%) in the pharmaceutical company Rafa Laboratories, the private equity fund FIMI is in preliminary talks to sell a 10%-15% stake to institutional investors. The accelerated growth in the field of automatic syringes for treating seizures due to exposure to biological weapons and the distribution of rare drugs in Europe allows FIMI to demand a high amount. The valuation for this sale is expected to be double the amount FIMI paid when it acquired control of Rafa at the end of 2020.
Investment
growth-positive
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector
Rafa Laboratories LTD has received FDA approval for its first in market 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The product was developed in partnership with the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The autoinjector can be used to treat seizures resulting from nerve agent exposure and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector. The product was developed in Israel and is already sold under EUA in other territories.
PartnersCustomers
growth-positive
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
Rafa Laboratories has announced a strategic collaboration with ExCEEd Orphan for medicines addressing rare diseases in Central and Eastern Europe (CEE) and Israel. Rafa will invest an undisclosed amount in ExCEEd to strengthen its market access capabilities in the region. The collaboration aims to bring new medicines for rare diseases to both CEE and Israel. The worldwide orphan drug market is growing rapidly, and Rafas investment in ExCEEd demonstrates its commitment to becoming a leading player in this field. ExCEEd has already signed agreements with leading pharma companies, and the collaboration with Rafa will further facilitate access to medicines for rare diseases in CEE countries.
PartnersInvestmentExpand
growth-negative
FIMI buys Rafa from Sackler family at NIS 700m valuation
The Sackler family has sold its controlling stake in Rafa Laboratories Ltd. due to the fallout from the opioid scandal. FIMI Opportunity Funds has acquired a 90% stake in Rafa Laboratories at a company valuation of NIS 700 million. Rafa Laboratories is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for marketing in Israel. The company has hundreds of employees and a factory in Jerusalem. The entry of FIMI as the senior partner will allow the continued operations of the factory and the promotion of Rafas business in Israeli and overseas markets.
Acquisition
growth-negative
Sackler family in talks to sell control of Rafa to FIMI
The Sackler family is selling its 78% stake in Rafa Laboratories Ltd. due to its involvement in the opioid affair in the US. FIMI Opportunity Funds is in talks to acquire Rafa at a company valuation of NIS 700 million. The Sackler family owns Purdue Pharma, which filed for bankruptcy protection after the opioid scandal. Rafa is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for the Israeli market. This acquisition would be one of FIMIs largest in recent years and expands its healthcare portfolio.
Acquisition
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.rafa.co.il/en |
| Careers | Careers page |
Locations
Shlomo Momo ha-Levi St 5, Jerusalem, Israel
Photos & Videos
No files yet
Rafa Laboratories Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsTags (9)
pharma-companiesdrug-designdrug-discoveryhealthcarepharmaceuticalsmanufacturingmarketinglaboratoriesbiotechnologyGeographic Markets
IsraelGermanyRafa Laboratories Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
0
Total rounds
0
Investors
Public Offering / Exit
MNAEvent
Oct 2020
Undisclosed
Rafa Laboratories Lifecycle
All Events
MNAEvent
Oct 2020
Undisclosed
Rafa Laboratories News
8 articles
growth-positive
שווי של 1.2 מיליארד שקל: פימי במגעים למכירת 10%–15% מרפא
Almost four years after acquiring a controlling stake (88%) in the pharmaceutical company Rafa Laboratories, the private equity fund FIMI is in preliminary talks to sell a 10%-15% stake to institutional investors. The accelerated growth in the field of automatic syringes for treating seizures due to exposure to biological weapons and the distribution of rare drugs in Europe allows FIMI to demand a high amount. The valuation for this sale is expected to be double the amount FIMI paid when it acquired control of Rafa at the end of 2020.
Investment
growth-positive
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector
Rafa Laboratories LTD has received FDA approval for its first in market 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The product was developed in partnership with the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The autoinjector can be used to treat seizures resulting from nerve agent exposure and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector. The product was developed in Israel and is already sold under EUA in other territories.
PartnersCustomers
growth-positive
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
Rafa Laboratories has announced a strategic collaboration with ExCEEd Orphan for medicines addressing rare diseases in Central and Eastern Europe (CEE) and Israel. Rafa will invest an undisclosed amount in ExCEEd to strengthen its market access capabilities in the region. The collaboration aims to bring new medicines for rare diseases to both CEE and Israel. The worldwide orphan drug market is growing rapidly, and Rafas investment in ExCEEd demonstrates its commitment to becoming a leading player in this field. ExCEEd has already signed agreements with leading pharma companies, and the collaboration with Rafa will further facilitate access to medicines for rare diseases in CEE countries.
PartnersInvestmentExpand
growth-negative
FIMI buys Rafa from Sackler family at NIS 700m valuation
The Sackler family has sold its controlling stake in Rafa Laboratories Ltd. due to the fallout from the opioid scandal. FIMI Opportunity Funds has acquired a 90% stake in Rafa Laboratories at a company valuation of NIS 700 million. Rafa Laboratories is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for marketing in Israel. The company has hundreds of employees and a factory in Jerusalem. The entry of FIMI as the senior partner will allow the continued operations of the factory and the promotion of Rafas business in Israeli and overseas markets.
Acquisition
growth-negative
Sackler family in talks to sell control of Rafa to FIMI
The Sackler family is selling its 78% stake in Rafa Laboratories Ltd. due to its involvement in the opioid affair in the US. FIMI Opportunity Funds is in talks to acquire Rafa at a company valuation of NIS 700 million. The Sackler family owns Purdue Pharma, which filed for bankruptcy protection after the opioid scandal. Rafa is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for the Israeli market. This acquisition would be one of FIMIs largest in recent years and expands its healthcare portfolio.
Acquisition
growth-positive
Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease ("IBD", Crohn's and colitis)
Panaxia Pharmaceutical Industries Israel and Rafa have signed a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company. They will co-develop medical cannabis products for patients suffering from Inflammatory Bowel Disease. The products will be delivered using a conventional pharmaceutical delivery system, increasing accessibility to eligible patients. The active ingredients in the cannabis suppositories are absorbed quickly and provide a speedy physical response. This collaboration aims to revolutionize the accessibility of medical cannabis in Israel.
Partners
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents
growth-positive
Nerve Gas Attack: New Treatment Cleared, But More Drugs Are Needed
The U.S. government has authorized the use of a new drug injector manufactured by Rafa Laboratories Ltd., a pharmaceutical company based in Israel, to treat people exposed to nerve gas. The drug contained in the injector is atropine. However, medical experts argue that other drugs, such as pralidoxime and midazolam, are also needed for effective treatment. The FDAs emergency use authorization for the atropine injector is seen as a positive growth for Rafa Laboratories Ltd. The company is urged to focus on approving other drugs that work differently from atropine. The article highlights the importance of having a variety of drugs to treat nerve gas exposure and the need for stockpiling and preparedness in case of a chemical nerve agent threat.
Customers
Rafa Laboratories Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 143 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Rafa Laboratories Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 511033789 |
| Crunchbase | rafa-laboratories-ltd |
| Phone | +97225893939 |
| Creator | Sharon Shapira |
| Creator email | shapira.sharon2@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-18T00:00:00.000Z |
| Created | 2014-11-09T00:00:00.000Z |
| Status detail | Acquired by FIMI Opportunity Funds on Oct, 2020 |